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Background: Synchronous development of primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma
has been reported rarely. In literature review, there have been only 35 reported cases of synchronous hepatocellular
carcinoma and intrahepatic cholangiocarcinoma, and most of these tumors developed in patients with hepatitis
C-related liver cirrhosis. Here, we present synchronous development of hepatocellular carcinoma and intrahepatic
cholangiocarcinoma in two patients with chronic B-viral hepatitis.
Case presentation: Two patients with chronic hepatitis B were referred to our hospital due to a hepatic mass.
Patient 1 had a 6.4 cm multinodular hepatic mass in the left lobe and a small nodule in the right lobe. Patient 2
had a 4.3 cm hypervascular mass in the right lobe and a 1.1 cm nodule in the left lobe. The pre-operative diagnosis
of both cases was hepatocellular carcinoma with metastatic nodule, however, surgical resection pathology revealed
that hepatocellular carcinoma and intrahepatic cholangiocarcinoma existed independently in the other side of the
liver in both cases. Additionally, the background liver histology of both cases was hepatitis B-related chronic hepatitis
without cirrhotic change.
Conclusion: Our cases suggest that hepatitis B virus infection can also predispose to development of double
liver cancers.
Keywords: Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma, Double primary liver cancer, Hepatitis B
virus, Chronic liver diseaseBackground
Although hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (ICC) are the two major forms of
primary liver cancer, coincidence of both in a single patient
is very rare [1,2]. Moreover, synchronous development
of double cancer is exceedingly rare, reported in only 35
cases worldwide [3-6]. Even though the clinicopathological* Correspondence: drpjy@yuhs.ac
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reproduction in any medium, provided the orfeatures of the phenomenon have not been clearly in-
vestigated, previous studies suggested a relationship be-
tween hepatitis C virus (HCV) and the double primary
liver cancer [3,4]. These results could be explained by
the fact that many of these cases were reported in
Japan, where HCV infection is endemic, and HCV-related
cirrhosis is associated with carcinogenesis, giving rise to
both HCC and ICC [7,8]. In contrast of HCV-infections,
the relationship between hepatitis B virus (HBV) infection
and double primary tumor has not been clarified yet,
although it is known that HBV is an important risk factor
for development of HCC and ICC [9,10]. Here, we present
two chronic hepatitis B cases that resulted in synchronous
development of HCC and ICC in separate hepatic sites.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Case 1
A 66-year-old woman with chronic hepatitis B was referred
to our clinic due to a hepatic mass. The patient had
no other apparent conditions. Laboratory tests, including
platelet counts and liver function, were normal. Hepatitis
B surface antigen (HBsAg) was positive and hepatitis B
e antigen (HBeAg) was negative. The serum hepatitis
B virus deoxyribonucleic acid (HBV-DNA) level was
2,490 IU/ml. Anti-HCV antibody was negative. Of the
tumor markers tested, alpha-fetoprotein (AFP) was
3.54 IU/ml, protein induced vitamin K antagonist
(PIVKA-II) was 22 mAU/ml, carcinoembryonic anti-
gen (CEA) was 4.28 ng/ml, and carbohydrate antigen
19–9 (CA19-9) was 0.1 U/ml. She was a social-drinker,
and had no metabolic impairment.
Computed tomography (CT) and dynamic magnetic
resonance imaging (MRI) revealed a 6.4 cm multinodular
hepatic mass with heterogeneous arterial rim enhance-
ment in the left lobe (S2 and 3), and a small nodule in
the right lobe (S7) (Figure 1A-C). The larger mass was
suspected to be an HCC and the smaller mass was
suspected to be a metastatic nodule, but due to the
atypical radiological findings of the main tumor and
the normal tumor marker levels, we were unable to
confirm the preoperative diagnosis. The tumors were
resected via left lateral sectionectomy (S2 and S3) and
wedge resection of S7.Figure 1 Dynamic magnetic resonance imaging (MRI) of the liver (A-C
specimens (D, E). A 6.4 cm-sized main mass (arrow) showed heterogeneo
phase (C), and small nodule (arrowhead) in the right lobe also showed rim
(immunohistochemical staining of Filamin-A). E: An Edmondson-Steiner graUnexpectedly, the pathological examination revealed that
the main mass in the left lobe was moderately differen-
tiated ICC (Figure 1D, positive immunohistochemical
staining of Filamin-A) and the small nodule in the right
lobe was an HCC of Edmondson-Steiner grade I (Figure 1E).
According to histopathological classification proposed
by Komuta et al., the tumor in the left lobe was pure
mucin-producing adenocarcinoma [11]. Additionally, it
was determined that the ICC had metastasized to two
lymph nodes. Histology of the hepatic parenchyma revealed
chronic hepatitis caused by hepatitis B virus with minimal
lobular activity and Metavir grade 1 fibrosis.
For one month following surgical resection, the patient
was treated with adjuvant chemotherapy using gemcita-
bine hydrochloride, after which she underwent six cycles
of chemotherapy. At seven months post resection, there
was no evidence of recurrence.
Case 2
A 68-year-old woman with chronic B viral hepatitis was
referred to our hospital due to a hepatic mass. She was
asymptomatic and her laboratory tests were normal.
HBsAg was positive and HBeAg was negative. The
serum HBV-DNA level was 217,000 IU/ml. Anti-HCV
antibody was negative. Of the tumor markers tested,
AFP was 46.54 IU/ml and PIVKA-II was more than
2,000 mAU/ml. The CEA and CA19-9 level was
1.03 ng/ml and 12.8 U/ml, respectively. She was a, 3D T1-weighted gradient echo image) and histology of surgical
us rim-enhancement throughout arterial (A), portal (B), and delayed
enhancement. D: A moderately differentiated cholangiocarcinoma
de I, trabecular type hepatocellular carcinoma. (H&E, D: ×200, E: ×100).
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MRI revealed a 4.3 cm hypervascular mass with internal
hemorrhage in segment 5 (S5), and the radiological
appearance of the tumor suggested an HCC. Additionally,
a 1.1-cm solid lesion with capsular retraction was iden-
tified in the left lobe (S3) and suspected as a small
HCC or a bile duct adenoma (Figure 2A-C). The patient
underwent anterior sectionectomy of the right lobe and
an S3 segmentectomy. The pathological examination
confirmed that the right lobe tumor was an HCC of
Edmondson-Steiner grade II/III (Figure 2E). The left
lobe nodule was confirmed as a well-differentiated ICC
(Figure 2D). ICC in the left lobe was classified into pure
mucin-producing adenocarcinoma by histopathological
classification. Histology of the hepatic parenchyma revealed
chronic hepatitis caused by hepatitis B virus with mild
lobular activity and Metavir grade 2 fibrosis. There was no
evidence of recurrence at two years following resection.
Conclusion
The present report describes two cases of synchronous
development of HCC and ICC in different liver lobes
with hepatitis B virus infection. Although it is extremely
rare for the liver to be affected by two types of primary
tumors simultaneously, new insights of stem cell-derived
carcinogenesis might be able to explain development
mechanism of these tumors as they suggested that hepaticFigure 2 Dynamic magnetic resonance imaging (MRI) of the liver (A-C
surgical specimens (D-E). The right lobe mass (arrow) appears as a high-i
(B: portal phase, C: delayed phase). The satellite lesion (arrowhead) in the le
the central area during the arterial and portal phases (A, B), and low-intens
well-differentiated cholangiocarcinoma. E: Edmondson-Steiner grade II/III, t
(H&E, D, E: ×200).progenitor cell (HPC) can differentiate into either hepato-
cytes or cholangiocytes [11,12]. According this theory,
HPC-related tumors can display a whole spectrum of
phenotypes with varying hepatocellular and choloangio-
cellular differentiation characteristics [11]. For instance,
when Komuta et al. compared gene expression of cho-
langiolocellular carcinoma, a subtype of ICC, with those
of HCC with HPC characteristics, a high homology was
demonstrated between two groups and these results
suggested that ICC and HCC may share common car-
cinogenesis [13].
Along with advanced comprehension of carcinogenesis,
there have been additional efforts to find clinicopatho-
logical factors related with these tumors [2,3]. Previ-
ous reports noted a relationship between chronic liver
inflammation and multiple primary liver neoplasms, as
most cases involved chronic hepatitis or cirrhosis [3,4].
Moreover, these relationships were theoretically supported
by recent studies which indicated that chronic liver
inflammation played a key role at the molecular level
in primary liver cancers, including HCC and ICC [14-16].
Thus, any etiology causing chronic liver inflammation
could be a potential risk factor for coincidental liver
tumors. Of these, HCV infection is considered to have
one of the closest associations with development of
double primary tumor of liver [9]. Indeed, chronic
hepatitis C infection is a dominant risk factor for ICC, T1-weighted spoiled gradient echo image), and histology of
ntensity lesion during the arterial phase (A) with delayed wash-out
ft lobe has peripheral signal enhancement and slightly higher signal in
ity signal during delayed phase (C). D: Frozen section pathology, a
rabecular- and pseudoglandular-type hepatocellular carcinoma.
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multiple liver tumors with HCC and ICC have been
detected in livers infected with HCV [7,8].
In contrast to HCV infection, HBV infection has not
been associated with the development of synchronous
liver tumors, despite being the most common cause of
chronic liver disease [17]. Of 35 reported worldwide cases
of multiple primary liver tumors, only three patients
had HBV infection (8.6%) [3-5]. Especially, in Korea,
where the prevalence of HBV infections is considerably
high [18], only one case of HBV infection has been
reported [5]. However, like HCV infection, HBV infection
is a well-known risk factor of HCC development [9,19],
and recent studies including one meta-analysis strongly
suggest that HBV infection also increases the risk of ICC
significantly [10,20-22]. Moreover, recent studies indicated
that hepatitis B virus-associated ICC and HCC shared
common disease process for carcinogenesis in the
cross-sectional design [12]. These results suggest that
not only does HBV cause synchronous development of
HCC and ICC, but also that the low prevalence of these
tumors in HBV infection may be due to underdiagnosis
in clinical practice.
Indeed, Inaba et al. stated that most cases of multiple
liver tumors were diagnosed initially as HCCs, with only
about 20% being accurately diagnosed as separate
primary liver tumors prior to treatment [3]. There are
several possible explanations for this. Firstly, recent
improvements in radiologic imaging allow the clinician to
diagnose many HCCs without liver biopsy [23]. However,
in some cases, ICC can be confused radiologically with
HCC, and small tumors or malignant nodules may not
resemble a typical HCC or ICC. In case 2 of this report,
the main mass had characteristics typical of HCC with
increased AFP and PIVKA-II, and the 1.1 cm left lobe
mass did not have the typical features of an ICC. There-
fore we did not suspect the possibility of synchronous
primary tumors. Secondly, paradoxically, it is possible
that the clinician’s knowledge of a patient’s HBV or HCV
infection could affect the approach to cancer diagnosis,
because the clinician may have a preconception of a
specific tumor. In case 1 of this report, although the main
tumor had ambiguous radiologic morphology and the
tumor markers AFP and PIVKA were within normal
ranges, our preoperative diagnosis was an HCC. On
review of the CT and MRI scans after surgical resection,
we admitted that the main tumor had several features of
an ICC, but it was still difficult to confirm the diagnosis.
In this case, the diagnosis might have been further
confused by the knowledge of a higher prevalence of HCC
than ICC in HBV patients. Such difficult preoperative
diagnosis suggests that there may have been many
unproven cases of multiple primary cancers in past
cases. Although the prevalence of synchronous primaryhepatic tumors is very low, these cases emphasize the
importance of a delicate approach to diagnosis of liver
cancer. If radiological examination or tumor markers are
atypical of a specific cancer, pathological confirmation by
liver biopsy should be considered especially in chronic
hepatitis patients, even if a certain type of tumor is
strongly suspected.
Interestingly, in our cases, the double primary cancer
developed from non-cirrhotic liver with HBV-related
chronic hepatitis, whereas most of these tumors did
from HCV-related cirrhotic livers [3,4]. These results are
consistent with the fact that HBV-related HCC could
have developed from non-cirrhotic livers and that ICC
and HCC share similar mechanism of tumorigenesis in
the setting of chronic inflammation [24]. However, the
mechanism for developing double liver cancer from liver
with HBV infection needs to be further investigated.
As the incidence of synchronous primary liver tumors
is extremely low, treatment of these patients is challenging.
Although several other methods have been tried, surgical
resection is regarded as the treatment of choice because it
can provide an accurate diagnosis as well as a chance of
cure. But there is no definite guideline after surgical resec-
tion, and the postoperative plan should be individualized.
We are aware of the limitations of our study. Most of all,
several immunohistochemical markers, which represent
human hepatic stem cell or mature cholangiocytes such
as epithelial cell adhesion molecule (EpCAM) or secretin
receptor, were not available in our cases. Although the
novel classification of cholangiocarcinoma proposed
by Komuta et al., which is based on histopathological
features, might help to identify characteristics of the
tumors, these limitations would not allow us to understand
carcinogenesis of our cases thoroughly [11,25]. Therefore,
application of novel classification of cholangiocarcinoma
and appropriate immunohistochemical stain of tumor tis-
sue should be considered in cases with double liver cancer.
In summary, we report here rare cases of synchronous
development of HCC and ICC in patients infected B-viral
chronic hepatitis. Accurate diagnosis and individualized
treatment is important. Further research is needed because
knowledge of the biology of these tumors might shed light
on the behavior of HCC and ICC and elucidate a more
appropriate treatment plan.
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